Cargando…

Efficacy of telavancin for treatment of surgical site infections

Detalles Bibliográficos
Autores principales:	Wilson, SE, Stryjewski, ME, Fowler, VG, Young, D, Jacobs, F, Hopkins, A, Barriere, SL, Kitt, MM, Corey, GR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088399/ http://dx.doi.org/10.1186/cc6249

Ejemplares similares

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

Late ventilator-associated pneumonia: analysis of baseline characteristics and clinical outcomes in the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART
por: Tsarenko, SP, et al.
Publicado: (2010)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Is admission of hematologic malignancies in the ICU justified?
por: Gasparovic, VG, et al.
Publicado: (2015)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
por: Polyzos, Konstantinos A., et al.
Publicado: (2012)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Perioperative and short-term results of the surgical treatment of infective endocarditis
por: Moşteoru, SL, et al.
Publicado: (2012)

PReS-FINAL-2233: Retrospective analysis of different treatment strategies in chronic non-bacterial osteomyelitis
por: Kostik, MM, et al.
Publicado: (2013)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Multimodal approach for surgical site infection prevention – results from a pilot site in Kenya
por: Ntumba, P, et al.
Publicado: (2015)

Factors associated with alcohol use among minority female adolescents receiving preventive text messaging for underage drinking
por: Sawant, Meenal, et al.
Publicado: (2015)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

Introduction of bundle of care and effect on surgical site infections in patients taken for elective surgical procedures
por: Waheed, A, et al.
Publicado: (2014)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Risk factors of surgical site infection post cesarean section
por: Alishaq, MA, et al.
Publicado: (2011)

Surgical site infection among patients undergoing cardiac transplantation
por: Rodrigues, JASN, et al.
Publicado: (2015)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

IL-6 and ITS correlation to stress hyperglycemia in diabetic and non-diabetic critically ILL septic patients
por: Fayed, AM, et al.
Publicado: (2015)

Genetically restricted HIV-1 sub populations are associated with and migrate within metastatic sites of AIDS-related lymphoma
por: McGrath, MS, et al.
Publicado: (2009)

Efficacy of surgical antiseptic handrub containing PHMB
por: Noguchi, E, et al.
Publicado: (2011)

Reply to Tarchini
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Meeting global standards for hand sanitizer efficacy: formulation matters
por: Edmonds, SL, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_11arvn6vamtscbogql618861ls